BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 18076066)

  • 21. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
    Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
    Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor.
    Aoki H; Mizuno M; Natsume A; Tsugawa T; Tsujimura K; Takahashi T; Yoshida J
    Cancer Immunol Immunother; 2001 Nov; 50(9):463-8. PubMed ID: 11761440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glioma stem cell-targeted dendritic cells as a tumor vaccine against malignant glioma.
    Ji B; Chen Q; Liu B; Wu L; Tian D; Guo Z; Yi W
    Yonsei Med J; 2013 Jan; 54(1):92-100. PubMed ID: 23225804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effect of dendritic cells loaded with a fusion mRNA encoding tyrosinase-related protein 2 and enhanced green fluorescence protein on B16 melanoma.
    Fukui M; Nakano-Hashimoto T; Okano K; Maruta Y; Suehiro Y; Hamanaka Y; Yamashita H; Imai K; Kawano MM; Hinoda Y
    Tumour Biol; 2004; 25(5-6):252-7. PubMed ID: 15627888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.
    Prins RM; Wang X; Soto H; Young E; Lisiero DN; Fong B; Everson R; Yong WH; Lai A; Li G; Cloughesy TF; Liau LM
    J Immunother; 2013 Feb; 36(2):152-7. PubMed ID: 23377664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
    Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
    Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
    Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
    Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
    Hegmans JP; Hemmes A; Aerts JG; Hoogsteden HC; Lambrecht BN
    Am J Respir Crit Care Med; 2005 May; 171(10):1168-77. PubMed ID: 15764728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma.
    Onishi H; Morisaki T; Baba E; Nakamura M; Inaba S; Kuroki H; Matsumoto K; Katano M
    Anticancer Res; 2011 Nov; 31(11):3995-4005. PubMed ID: 22110233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.
    Iizuka Y; Kojima H; Kobata T; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2006 Feb; 118(4):942-9. PubMed ID: 16152596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.
    Pellegatta S; Poliani PL; Stucchi E; Corno D; Colombo CA; Orzan F; Ravanini M; Finocchiaro G
    Neuro Oncol; 2010 Apr; 12(4):377-88. PubMed ID: 20308315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
    Shimizu K; Thomas EK; Giedlin M; Mulé JJ
    Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
    Yamanaka R; Abe T; Yajima N; Tsuchiya N; Homma J; Kobayashi T; Narita M; Takahashi M; Tanaka R
    Br J Cancer; 2003 Oct; 89(7):1172-9. PubMed ID: 14520441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model.
    Chirasani SR; Leukel P; Gottfried E; Hochrein J; Stadler K; Neumann B; Oefner PJ; Gronwald W; Bogdahn U; Hau P; Kreutz M; Grauer OM
    Int J Cancer; 2013 Feb; 132(4):843-53. PubMed ID: 22752934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.